key: cord-0730519-x3vfiwm5
authors: Canaday, David H; Carias, Lenore; Oyebanji, Oladayo A; Keresztesy, Debbie; Wilk, Dennis; Payne, Michael; Aung, Htin; St. Denis, Kerri; Lam, Evan C; Rowley, Christopher F; Berry, Sarah D; Cameron, Cheryl M; Cameron, Mark J; Wilson, Brigid; Balazs, Alejandro B; Gravenstein, Stefan; King, Christopher L
title: Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents
date: 2021-05-16
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab447
sha: 761abd05cd26da4ee8f5fdfc65192eed8f04e841
doc_id: 730519
cord_uid: x3vfiwm5

After BNT162b2 mRNA vaccination, antibody levels to spike, receptor binding domain (RBD) and virus neutralization were examined in 149 nursing home (NH) residents and 110 health care worker controls. SARS-CoV-2-naive NH residents median post-2nd vaccine dose antibody neutralization titers are ¼ that of SARS-CoV-2-naive healthcare workers.

The SARS-CoV-2 pandemic has severely affected nursing home (NH) residents prompting their prioritization for early vaccination. Recent reports show the BNT162b2 mRNA vaccine reduces COVID-19 hospitalization and mortality [1] [2] [3] [4] . BNT162b2 mRNA vaccine immunogenicity has been reported in some healthy 65-85 years olds [1] , however no immunogenicity data exist for NH residents to this vaccine. NH residents often have multiple morbidities, medications, and advanced age that individually and collectively can blunt immune response. Here, we examined antibody response to BNT162b2 mRNA vaccine in NH residents that were SARS-CoV-2-naive where the vaccine is presumed to be neoantigen-like and individuals that had prior SARS-CoV-2 infection where the vaccine would be boosting prior responses.

We obtained New England IRB study approval and consented subjects per protocol. We approached nursing home's leadership to gain entry to 4 NH buildings and recruit residents for vaccination with and without prior SARS-CoV-2 infection and healthcare workers as controls. Controls included vaccinated individuals with and without prior SARS-CoV-2 infection, and unvaccinated individuals convalescent from prior SARS-CoV-2 infection.

Prior SARS-CoV-2 infection was determined by PCR, antigen test, and/or high antibody titer to SARS-CoV-2 spike and receptor binding domain (RBD).

Anti-spike and anti-RDB assay: Stabilized full-length S protein (aa 16-1230, with furin site mutated) and RBD (aa 319-541) were conjugated to magnetic microbeads (Luminex). Antigenspecific IgG is detected in patient serum/plasma using PE-conjugated Donkey F(ab)2 anti-human IgG, with Fcγ (Jackson Immunological) added. Using the Magpix assay system (BioRad, Inc), the mean A c c e p t e d M a n u s c r i p t 4 fluorescent index is recorded. To provide an internal standard and control for plate to plate variation, a pool of convalescent plasma was generated from people with known prior SARS-CoV-2 infection and ran a standard curve of half log-dilutions starting at a 1:100 dilution on each plate. A relative antibody unit (AU) value of 4000 was ascribed to the 1:100 dilution. MFI values were interpolated from this curve to generate the AU values presented. A receiver operating curve was generated using 167 pre-SARS-CoV-2 serum control samples and 66 SARS-CoV-2 convalescent samples to determine cut-off values for a convalescent antibody levels with a specificity of 99% and sensitivity of 98% using antibodies to both S and RBD.

To compare the neutralizing activity of vaccine recipients' sera against coronaviruses, we produced lentiviral particles pseudotyped with vaccine strain spike protein as previously described [5] . Neutralization assays and readout were performed on a Fluent Automated Workstation (Tecan) liquid handler using 384-well plates (Grenier) [6] . Three-fold serial dilutions ranging from 1:12 to 1:8,748 were performed for each serum sample before adding 50-250 infectious units of pseudovirus for 1 hour. Percent neutralization was determined by subtracting background luminescence measured in cell control wells (cells only) from sample wells and dividing by virus control wells (virus and cells only). pNT50 values were calculated by taking the inverse of the 50% inhibitory concentration value for all samples with a pseudovirus neutralization value of 80% or higher at the highest concentration of serum.

We used R 4.0.3 for all statistical analyses. Unless otherwise specified, presented p-values are unadjusted.

We recruited 149 NH residents, (age range 48-99, median age 76), 110 healthcare worker controls (age range 26-78; median age 48), and 22 unvaccinated convalescent controls (age range 25-61, median age 53) 29-94 days after SARS-CoV-2 infection with asymptomatic or mild disease (Supplemental Table 1 ). All NH residents and 71 of 110 healthcare worker controls provided baseline 

We show most NH residents have produced antibodies to the BNT162b2 mRNA vaccine but those without prior SARS-CoV-2 infection have significantly lower antibody levels than younger nonfrail control participants with few exceptions. It is interesting to note that individuals with prior SARS-CoV-2 infection, including NH residents, have higher post-vaccination antibody levels than SARS-CoV-2 naive individuals and are similar to those in vaccinated convalescent controls, a trend more noticeable for women. However, it is difficult to disentangle this finding from a survivorship bias for these NH residents; possibly, non-responders may have been culled from contributing to our sample based on survival or ability to recruit them due to post-COVID outcomes affecting their ability to consent and participate in our study. Therefore, those SARS-CoV-2-naive NH residents' blunted antibody responses have important implications regarding the interpretation of these net high titers of convalescent NH residents, regarding the quality and durability of protection afforded as neoantigen vaccines, and potentially as a breeding ground for vaccine-resistant variants.

The causes for the diminished response are not fully clear but older adults have reduced vaccine response to many different vaccines [7] [8] [9] , leading to the development of enhanced vaccines in order to overcome this age handicap such as the adjuvanted and higher dose influenza vaccines. reports of significant reductions in COVID-19 in NH after vaccination are encouraging, but it is not clear how sustained that protection will be. There is continued and even increased infection risk in NH expected as they relax visitation policies and confront vaccine hesitancy in some residents and especially among NH staff.

There may be differences in responses between the different vaccine platforms in NH residents. Although Walsh et al reported similarities in the antibody responses after BNT162b2 mRNA vaccination in a much healthier older population compared to younger individuals [1] , our data suggest that this does not hold in the more frail, older NH population. Poor vaccine immune responses in frail older adults with many multimorbidities could be exacerbated with the somewhat less immunogenic non-mRNA vaccine, such as an adenovirus vectored vaccine like the Ad26.COV2.S SARS-CoV-2 vaccine [10] . There is still much to do to fully understand how to optimally protect this most frail and vulnerable population from COVID-19. We urgently need better longitudinal evidence on vaccine effectiveness specific to NH resident populations, especially in the context of new more transmissible variants to inform best practices for NH infection control measures and outbreak prevention. Vaccine failure with a variant has already been reported in a skilled nursing facility in Kentucky [11] . We do not know if additional booster vaccination will rescue poor and nonresponders, making them more fit from the variant matching their vaccine's design, or to other variants of concern. We should presume a population setting with suboptimal vaccine uptake among staff and visitors and a substantial proportion of poor responders will place selective pressure for the development of new variants of concern. If an additional booster vaccine can improve protection, our results would support an approach in which we screen antibody responses after vaccination in NH residents to determine for whom an additional vaccine boost could be beneficial. Data on immune correlates of protection are needed as well.

A c c e p t e d M a n u s c r i p t

Post-vaccination anti-spike, anti-RBD and serum neutralization titers are shown. On the x axis, NH refers to NH residents and Control refers to the vaccinated younger healthcare workers or unvaccinated SARS-CoV-2 convalescent individuals. Points from male subjects appear as blue and points from female subjects appear as red. The dotted line in each panel is the median preimmunization value in the SARS-CoV-2-naive subjects. Anti-Spike and Anti-RBD differences in geometric means were assessed using t-tests of log-transformed values. Given observed points at upper and lower limits of detection in neutralizing titer assay (12-8748) the differences in distribution were assessed using the Wilcoxon rank-sum test. P-values were adjusted within assay (n = 6 tests per assay, Bonferroni method), and adjusted p-values < 0.001 are indicated with stars (***).

A c c e p t e d M a n u s c r i p t 

3P01AG027296-11S1, and U01 CA260539-01 and VA. Potential conflicts of interest: SG and DC are recipients of investigator-initiated grants to their universities from Pfizer to study pneumococcal vaccines and Sanofi Pasteur and Seqirus to study influenza vaccines. SG also does consulting for Seqirus

SG has spoken for Seqirus and Sanofi. S.G. reports personal fees from Pfizer and DSMB fees from Longevoron. DC consulting work for Seqirus

Harvard; and DSMB member for a trial of Zoledronic Acid in Parkinson's patients, outside the submitted work. CLK reports grants from Bill and Melinda Gates Foundation; and grants from NIH and VA, outside the submitted work

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Is the End of the Long-Term Care Crisis Within Sight? New COVID-19 Cases and Deaths in Long-Term Care Facilities Are Dropping

Short Term Impact of Nursing Home SARS-CoV-2 Vaccinations on New Infections, Hospitalizations and Deaths

COVID-19-neutralizing antibodies predict disease severity and survival

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Antibody response to influenza vaccination in the elderly: a quantitative review

Immunosenescence and human vaccine immune responses

Influence of immune aging on vaccine responses

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program -Kentucky

A c c e p t e d M a n u s c r i p t 9 A c c e p t e d M a n u s c r i p t